In a groundbreaking study poised to alter the landscape of sepsis research and treatment, scientists have unveiled the pivotal role of a specific subgroup of neutrophils characterized by the marker FOLR3 in the progression and severity of sepsis. This discovery not only sheds light on the complex immune dynamics at play during sepsis but also proposes FOLR3+ neutrophils as a promising new prognostic biomarker, potentially transforming clinical approaches to this life-threatening condition.
Sepsis, a disastrous systemic inflammatory response to infection, remains a leading cause of mortality worldwide despite advances in critical care. One of the hallmarks of sepsis is sustained neutrophilia, an increase in neutrophil counts in the blood. However, the cellular heterogeneity within this neutrophil population and its contribution to the disease’s progression and fatality has long eluded researchers. The recent study exploits cutting-edge single-cell and bulk RNA sequencing techniques to dissect the neutrophil compartment in septic patients, revealing five distinct subclusters that vary dramatically in their functional profiles and disease associations.
Among these subclusters, the FOLR3-positive neutrophils emerge as the predominant and terminally differentiated subset. These cells exhibit a hyper-inflammatory transcriptomic signature coupled with notably suppressed HLA (Human Leukocyte Antigen) expression. This immunological phenotype is particularly pronounced in non-survivors, suggesting a direct link between the abundance of FOLR3+ neutrophils and poor prognosis in sepsis patients. Such findings compel a closer examination of the molecular and cellular mechanisms controlled by these specialized neutrophils.
Remarkably, the study employed CellChat analysis, an advanced computational tool designed to infer intercellular communication networks, revealing that FOLR3+ neutrophils actively facilitate sepsis progression by recruiting platelets. This recruitment occurs through two key ligand-receptor axes: RETN-CAP1 and NAMPT-ITGB1. The interaction between these molecules orchestrates a hyper-inflammatory milieu, exacerbating tissue damage and systemic inflammation, which are central to sepsis pathophysiology.
Validation using external cohorts reinforced the clinical significance of FOLR3+ neutrophils. Patients exhibiting higher frequencies of these cells consistently demonstrated elevated 28-day mortality rates, underscoring their potential as robust prognostic indicators. This external verification lends credence to the idea that monitoring FOLR3+ neutrophil levels could guide clinical decision-making, enabling early identification of patients at higher risk and prompting more aggressive or targeted therapeutic interventions.
The quest to pinpoint the molecular drivers behind the specification of FOLR3+ neutrophils led researchers to identify HIF-1A (hypoxia-inducible factor 1-alpha) as a central transcription factor regulating their differentiation. Pseudotime analyses highlighted that as neutrophils progress toward terminal differentiation into FOLR3+ cells, HIF-1A activity intensifies, orchestrating the gene expression programs that bestow these cells with their distinctive hyper-inflammatory properties.
In vitro experiments provided compelling validation, demonstrating that both FOLR3 expression and HIF-1A levels are significantly elevated in neutrophils derived from septic patients. Genetic manipulation through overexpression or knockout of HIF-1A in neutrophils from both human patients and mouse models conclusively established the transcription factor’s direct regulatory control over the secretion of crucial pro-inflammatory cytokines, including IL-1β, TNF-α, IL-8, and IL-6. These cytokines are well-documented mediators of the systemic inflammation that underpins sepsis mortality.
By exacerbating the inflammatory milieu, FOLR3+ neutrophils not only foster the propagation of a deleterious immune response but also emerge as potential drivers of organ dysfunction and failure in sepsis. This finding challenges previous models that regarded neutrophilia as a uniform phenomenon, highlighting instead the heterogeneous contributions of distinct neutrophil subsets to disease outcomes. The study, therefore, offers a nuanced perspective that could inform the development of precision immunotherapies targeting these terminally differentiated cells.
The implications of these discoveries are far-reaching. Clinically, the use of FOLR3 as a biomarker opens avenues for rapid diagnostic assays capable of stratifying sepsis patients based on their neutrophil composition, potentially facilitating personalized treatment strategies. Therapeutically, targeting the HIF-1A pathway represents a novel and attractive strategy to modulate the deleterious inflammatory responses mediated by FOLR3+ neutrophils, possibly mitigating sepsis severity and improving survival.
Moreover, this research highlights the power of integrating single-cell transcriptomics with functional validation experiments to unravel the cellular and molecular complexity of human diseases. Such multi-dimensional approaches are critical for dissecting the immune system’s intricacies, particularly in syndromes like sepsis, where heterogeneity impedes the efficacy of one-size-fits-all therapies. By focusing on cell-specific pathways, future research can refine therapeutic targets with greater precision and fewer off-target effects.
The study also underscores the essential role of platelet-neutrophil interactions in sepsis pathology. Although platelets have traditionally been recognized for their roles in hemostasis, their contribution to inflammation and immune regulation is increasingly appreciated. The identified RETN-CAP1 and NAMPT-ITGB1 signaling axes invite further exploration of how modulating these interactions could disrupt the vicious cycle of hyper-inflammation characteristic of sepsis.
Importantly, the elevation of FOLR3+ neutrophils and their associated inflammatory signatures in non-survivors illuminate new prognostic markers that surpass classical parameters, such as neutrophil counts or generalized inflammatory markers. This refinement is critical in a clinical landscape where timely prognosis guides therapeutic intensity and resource allocation, particularly in intensive care settings.
Mechanistically, the connection between hypoxia signaling, via HIF-1A, and neutrophil differentiation bridges a gap in understanding how the hypoxic microenvironments commonly found in infected and injured tissues influence immune cell fate and function. This association extends the role of HIF-1A beyond its classical metabolic regulatory functions into immune cell lineage specification and function, reinforcing its position as a central node in sepsis immunopathogenesis.
Future investigations will need to elucidate the upstream triggers that elevate HIF-1A activity in neutrophils during sepsis and whether interventions at earlier stages can prevent the emergence of the pro-inflammatory FOLR3+ neutrophil subset. Additionally, dissecting the cross-talk between these neutrophils and other immune or stromal cells will provide a more comprehensive understanding of the inflammatory networks driving sepsis.
Ultimately, the identification of FOLR3+ neutrophils as key mediators of hyper-inflammation and mortality in sepsis marks a significant advance in the field of immunology and infectious diseases. This work paves the way for novel diagnostic, prognostic, and therapeutic paradigms that could translate into improved survival and quality of life for millions affected by sepsis worldwide.
As sepsis continues to challenge clinicians and researchers alike, the insights gained from this study exemplify the promise of single-cell technologies and systems biology in transforming our understanding of complex diseases. By pinpointing the cells and molecular pathways that exacerbate disease, science moves closer to taming one of the most formidable killers in modern medicine.
Subject of Research: Neutrophil heterogeneity and hyper-inflammatory mechanisms in sepsis; Identification of FOLR3+ neutrophils as a prognostic biomarker and the regulatory role of HIF-1A in their specification.
Article Title: FOLR3+ neutrophils contribute to sepsis by exacerbating hyper-inflammation
Article References:
Chen, F., Tan, H., Wang, D. et al. FOLR3+neutrophils contribute to sepsis by exacerbating hyper-inflammation.
Genes Immun (2026). https://doi.org/10.1038/s41435-026-00396-0
Image Credits: AI Generated
DOI: 01 April 2026
Tags: clinical implications ofFOLR3 positive neutrophils in sepsishyper-inflammatory neutrophil signaturesimmune cell heterogeneity in sepsisinflammation and immune dysregulation in sepsisneutrophil subpopulations and sepsis severityneutrophilia and sepsis mortalityprognostic biomarkers for sepsissingle-cell RNA sequencing in sepsis researchsuppressed HLA expression in sepsisterminal differentiation of neutrophils in infectiontranscriptomic profiling of neutrophils
